An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo
Figure 6
rhArg-Fc has an extended half-life in vivo. (a) Three CD1 mice were injected i.v. with 100 μg or 50 μg rhArg-Fc/mouse and bled at 1, 2, 4, 6, 24, 72 and 144 h after injection. The levels of rhArg-Fc were measured by ELISA. (b) The plasma levels of arginine were determined at 1, 2, 3, 4, 6, 8 and 12 days post-treatment with 30–300 IU/mouse of rhArg-Fc.
